Real-time Estimate
Cboe BZX
10:57:23 2024-05-06 EDT
|
5-day change
|
1st Jan Change
|
3.235
USD
|
-0.46%
|
|
+24.81%
|
+30.89%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,145
|
723.1
|
390.7
|
117.9
|
156.3
|
-
|
-
|
Enterprise Value (EV)
1 |
907
|
478.1
|
175.2
|
117.9
|
156.3
|
156.3
|
156.3
|
P/E ratio
|
-30.5
x
|
-7.11
x
|
-3.01
x
|
-0.95
x
|
-1.68
x
|
-1.84
x
|
-1.53
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2,669
x
|
2,892
x
|
-
|
-
|
-
|
-
|
15.2
x
|
EV / Revenue
|
2,669
x
|
2,892
x
|
-
|
-
|
-
|
-
|
15.2
x
|
EV / EBITDA
|
-39.4
x
|
-7.6
x
|
-3.65
x
|
-0.92
x
|
-1.28
x
|
-1.45
x
|
-
|
EV / FCF
|
-31
x
|
-11.5
x
|
-4.31
x
|
-1.13
x
|
-1.6
x
|
-1.33
x
|
-1.09
x
|
FCF Yield
|
-3.23%
|
-8.73%
|
-23.2%
|
-88.3%
|
-62.6%
|
-75.2%
|
-91.8%
|
Price to Book
|
5.21
x
|
-3.64
x
|
-1.1
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
33,664
|
36,836
|
47,352
|
47,936
|
48,106
|
-
|
-
|
Reference price
2 |
34.01
|
19.63
|
8.250
|
2.460
|
3.250
|
3.250
|
3.250
|
Announcement Date
|
21-03-24
|
22-02-28
|
23-03-23
|
24-03-26
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
5.2
|
0.429
|
0.25
|
-
|
-
|
-
|
-
|
10.3
|
EBITDA
1 |
-
|
-29.09
|
-95.11
|
-106.9
|
-128.5
|
-122.4
|
-107.9
|
-
|
EBIT
1 |
-
|
-30.1
|
-96.44
|
-108.1
|
-129.7
|
-110.1
|
-130.8
|
-158.5
|
Operating Margin
|
-
|
-7,016.08%
|
-38,576%
|
-
|
-
|
-
|
-
|
-1,538.9%
|
Earnings before Tax (EBT)
1 |
-
|
-35.85
|
-95.4
|
-106.5
|
-123.5
|
-106.7
|
-127.5
|
-156.3
|
Net income
1 |
-
|
-35.85
|
-95.4
|
-106.5
|
-123.5
|
-106.7
|
-127.5
|
-156.3
|
Net margin
|
-
|
-8,357.34%
|
-38,160.8%
|
-
|
-
|
-
|
-
|
-1,517.21%
|
EPS
2 |
-0.5300
|
-1.114
|
-2.760
|
-2.740
|
-2.580
|
-1.933
|
-1.766
|
-2.130
|
Free Cash Flow
1 |
-
|
-36.92
|
-63.14
|
-90.69
|
-104.1
|
-97.8
|
-117.6
|
-143.6
|
FCF margin
|
-
|
-8,606.99%
|
-25,255.2%
|
-
|
-
|
-
|
-
|
-1,394.17%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-10-06
|
21-03-24
|
22-02-28
|
23-03-23
|
24-03-26
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-23.32
|
-23.17
|
-24.03
|
-28.77
|
-25.88
|
-28.26
|
-28.64
|
-36.32
|
-34.75
|
-
|
-29
|
-30
|
-31
|
-32
|
EBIT
1 |
-23.7
|
-23.49
|
-24.35
|
-29.06
|
-26.18
|
-28.56
|
-28.93
|
-37.2
|
-35.02
|
-28.54
|
-26.22
|
-25.85
|
-27.7
|
-29.88
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-22.93
|
-23.39
|
-24.25
|
-28.91
|
-25.78
|
-27.54
|
-27.46
|
-35.75
|
-33.32
|
-26.92
|
-25.28
|
-24.96
|
-26.83
|
-28.74
|
Net income
1 |
-22.93
|
-23.39
|
-24.25
|
-28.91
|
-25.78
|
-27.54
|
-27.46
|
-35.75
|
-33.32
|
-26.92
|
-25.28
|
-24.96
|
-26.83
|
-28.74
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6800
|
-0.6300
|
-0.6500
|
-0.7700
|
-0.6900
|
-0.6300
|
-0.5800
|
-0.7500
|
-0.7000
|
-0.5600
|
-0.5416
|
-0.4993
|
-0.4611
|
-0.4567
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-15
|
22-02-28
|
22-05-04
|
22-08-09
|
22-11-03
|
23-03-23
|
23-05-11
|
23-08-01
|
23-11-07
|
24-03-26
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
238
|
245
|
216
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-36.9
|
-63.1
|
-90.7
|
-104
|
-97.8
|
-118
|
-144
|
ROE (net income / shareholders' equity)
|
-
|
-46.6%
|
-45.3%
|
-54.4%
|
-98.4%
|
-133%
|
-120%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-28.2%
|
-38.2%
|
-44.4%
|
-71.5%
|
-111%
|
-102%
|
-
|
Assets
1 |
-
|
127.1
|
249.7
|
240.1
|
172.7
|
95.71
|
125.4
|
-
|
Book Value Per Share
|
-
|
6.530
|
-5.390
|
-7.520
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-1.130
|
-1.800
|
-2.320
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.59
|
0.92
|
0.27
|
0.1
|
-
|
-
|
-
|
Capex / Sales
|
-
|
137.53%
|
369.6%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-10-06
|
21-03-24
|
22-02-28
|
23-03-23
|
24-03-26
|
-
|
-
|
-
|
Last Close Price
3.25
USD Average target price
11.5
USD Spread / Average Target +253.85% Consensus |
1st Jan change
|
Capi.
|
---|
| +30.89% | 156M | | +21.76% | 47.9B | | +46.62% | 41.42B | | -2.18% | 40.7B | | -6.20% | 28.92B | | +10.19% | 25.55B | | -20.87% | 19.27B | | -0.32% | 12.15B | | +31.04% | 12.14B | | -0.47% | 11.99B |
Other Biotechnology & Medical Research
|